Related Experiment Videos
Therapy for acute leukemias in children.
1East Tennessee State University, James H. Quillen College of Medicine, Johnson City.
Current Opinion in Oncology
|February 1, 1991
Summary
Childhood acute lymphocytic leukemia survival has improved. New therapies for acute myeloid leukemia and acute progranulocytic leukemia are being explored, including targeted treatments like all-trans retinoic acid.
Area of Science:
- Pediatric Oncology
- Hematology
- Pharmacology
Background:
- Childhood acute lymphocytic leukemia (ALL) treatments have advanced, improving cure rates.
- Acute myeloid leukemia (AML) survival remains poor, with only one-third of patients achieving long-term survival.
- Acute progranulocytic leukemia (APL) shows promise with targeted differentiation therapy.
Purpose of the Study:
- To review recent advances in pediatric leukemia therapies.
- To highlight novel treatment strategies for ALL, AML, and APL.
- To discuss pharmacologic studies aimed at optimizing drug delivery and efficacy.
Main Methods:
- Review of current therapeutic strategies for childhood leukemias.
- Discussion of high-dose chemotherapy regimens, including alternating methotrexate and 6-mercaptopurine for ALL.
- Exploration of intensive chemotherapy regimens for AML and targeted therapy for APL.
Main Results:
- Majority of childhood ALL patients achieve cure.
- High-dose chemotherapy regimens for AML are intensive and toxic.
- All-trans retinoic acid demonstrates in vitro responsiveness in APL, leading to complex responses without conventional chemotherapy.
Conclusions:
- Therapeutic advances have significantly improved outcomes for childhood ALL.
- Novel approaches are needed to improve survival rates for AML.
- All-trans retinoic acid represents a promising targeted therapy for APL, offering an alternative to conventional cytotoxic agents.